Companies / Decibel Therapeutics, Inc.
Decibel Therapeutics, Inc.
DBTXCIK 1656536
Activity
InsidersInstitutions
What the company's own insiders are buying and selling.| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Feb 17, 2021 | Orbimed Advisors LLC Director | Buy Open-market buy | Common Stock | $20.00M | +1.1M +40.67% | 3,843,206 | high |
| Feb 17, 2021 | Thompson Peter A. Director | Buy Open-market buy | Common Stock | $20.00M | +1.1M +40.67% | 3,843,206 | high |
| Feb 17, 2021 | Casdin Partners Master Fund, L.P. 10% owner | Buy Open-market buy | Common Stock | $10.35M | +575K +105.23% | 1,121,421 | high |
| Feb 17, 2021 | Orbimed Advisors LLC Director | Buy Open-market buy | Common Stock | $10.00M | +556K +169.46% | 883,418 | high |
| Feb 17, 2021 | Thompson Peter A. Director | Buy Open-market buy | Common Stock | $10.00M | +556K +169.46% | 883,418 | high |
| Feb 17, 2021 | Glaxosmithkline PLC Director | Buy Open-market buy | Common Stock | $2.70M | +150K +14.51% | 1,183,663 | high |
| Feb 17, 2021 | Foy Matthew Director | Buy Open-market buy | Common Stock | $2.70M | +150K +14.51% | 1,183,663 | high |
| Sep 15, 2021 | Reid Laurence CEO | Buy Open-market buy | Common Stock | $76.4K | +10K +63.10% | 25,849 | medium |